Esaxerenone: First Global Approval

Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects

(2018) Manabu Kato et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A DOUBLE BLIND PHASE III STUDY OF ESAXERENONE (CS-3150) COMPARED TO EPLERENONE IN PATIENTS WITH ESSENTIAL HYPERTENSION (ESAX-HTN STUDY)

(2018) S. Ito et al.   JOURNAL OF HYPERTENSION

Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans

(2018) Makiko Yamada et al.   DRUG METABOLISM AND DISPOSITION

[BP.02.01] TREATMENT WITH ESAXERENONE (CS-3150) IS ASSOCIATED WITH A SIGNIFICANT DOSE-DEPENDENT ANTIHYPERTENSIVE EFFECT IN ESSENTIAL HYPERTENSIVE PATIENTS

(2017) S. Ito et al.   JOURNAL OF HYPERTENSION

Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension

(2016) Shigeru Shibata et al.   HYPERTENSION RESEARCH

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY